ANNIE DANG: Open Payments
NPI 1083353288 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,473 in 111 payments from 18 companies in 2025. Trend: 2023 $62 · 2024 $1,489 · 2025 $1,473
Food & beverage: $1,473
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 17 | $221 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $210 |
| Novo Nordisk Inc | 21 | $202 |
| ABBVIE INC. | 30 | $180 |
| AstraZeneca Pharmaceuticals LP | 4 | $159 |
| Vanda Pharmaceuticals Inc. | 1 | $75 |
| Sumitomo Pharma America, Inc. | 4 | $69 |
| GlaxoSmithKline, LLC. | 3 | $59 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $47 |
| Corcept Therapeutics | 3 | $45 |
Products named: XIFAXAN, Ozempic, AIRSUPRA, MOUNJARO, FANAPT, GEMTESA, JARDIANCE, VRAYLAR.
Industry payments across KS — which companies pay providers there.
